Modality
Cell Therapy
MOA
CD47i
Target
PLK4
Pathway
Angiogenesis
LGSHNSCCIPF
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
~Jan 2019
→ ~Apr 2020
Phase 2
~Jul 2020
→ ~Oct 2021
Phase 3
~Jan 2022
→ ~Apr 2023
NDA/BLA
Jul 2023
→ Aug 2028
NDA/BLACurrent
NCT08032434
2,093 pts·IPF
2023-07→2028-08·Not yet recruiting
NCT03789699
1,510 pts·LGS
2025-02→2025-01·Terminated
3,603 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-01-101.2y agoPh3 Readout· LGS
2028-08-282.4y awayPh3 Readout· IPF
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
NDA/BLA
Not yet…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2025-01-10 · 1.2y ago
LGS
Ph3 Readout
2028-08-28 · 2.4y away
IPF
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08032434 | NDA/BLA | IPF | Not yet recr... | 2093 | EDSS |
| NCT03789699 | NDA/BLA | LGS | Terminated | 1510 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BGN-3859 | BeiGene | Approved | PSMA | |
| Zanurapivir | Neurocrine | NDA/BLA | EGFR |